Athersys (NASDAQ:ATHX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Athersys (NASDAQ:ATHX) in a research note issued to investors on Monday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

The stock has a market cap of $833,000.00, a PE ratio of 0.00 and a beta of -0.90. Athersys has a one year low of $0.01 and a one year high of $1.99.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.